New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39231392.
- Also identified by DOI 10.1200/JCO.24.01147 and PMC identifier 11521153.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the article that accompanies this editorial, Dr. Solomon and colleagues present a post-hoc analysis of investigator-assessed efficacy outcomes, safety, and biomarker analyses encompassing approximately 5 years’ worth of data from the CROWN trial (NCT03052608) of lorlatinib compared with crizotinib in patients with treatment naïve advanced / metastatic ALK+ NSCLC demonstrating a PFS benefit for lorlatinib which exceeds 5 years and a 96% probability of preventing brain metastases within this time frame. These updated data are unprecedented for the treatment of ALK+ NSCLC, and for NSCLC treated with targeted therapies in general, making a compelling argument for lorlatinib as the preferred first line ALK TKI.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Lactams
- Anaplastic Lymphoma Kinase
- Aminopyridines
- Progression-Free Survival
- Lactams, Macrocyclic
- Pyrazoles